

Lantheus Medical Imaging, Inc. Announces Agreement with MDS Nordion to Secure Additional Supply of Molybdenum-99 (Mo-99), a Key Medical Isotope

July 8, 2010 4:11 PM ET

-- Agreement Reinforces Lantheus' Commitment to Providing Medical Isotopes for Nuclear Medicine Community --

N. BILLERICA, Mass. (July 8, 2010) – [Lantheus Medical Imaging, Inc.](#), a worldwide leader in diagnostic medical imaging, today announced that it has signed a new manufacturing and supply agreement with MDS Nordion to purchase molybdenum-99 (Mo-99), the parent isotope of technetium-99m (Tc-99m). Mo-99 is used in Lantheus Medical Imaging's TechnoLite® (Technetium Tc99m Generator) generators, which are sold throughout the world, and which produce Tc-99m, a medical isotope widely used in nuclear medicine imaging.

Under terms of the new agreement, Lantheus will begin receiving additional supply of Mo-99 on a weekly basis once the National Research Universal (NRU) reactor is back online, which is currently anticipated to be at the end of July 2010¹. The contract is in place until July 31, 2011.

"Our agreement with MDS Nordion is part of Lantheus Medical Imaging's aggressive supply chain strategy to strengthen our Mo-99 supply by working with major suppliers around the world in helping to meet the medical isotope needs of our customers in North America," said Don Kiepert, President and Chief Executive Officer, Lantheus Medical Imaging, Inc. "Lantheus continues to work diligently with our supply partners to maximize Mo-99 supplies so that patients can have access to critical nuclear imaging diagnostics."

"We look forward to working with MDS Nordion to increase access to Mo-99 supply once the NRU reactor returns to service," said Bill Dawes, Vice President of Manufacturing and Supply Chain, Lantheus Medical Imaging, Inc. "This agreement is yet another action that Lantheus has taken to obtain additional supply of Mo-99 and it underscores the company's commitment to help stabilize the worldwide Mo-99 shortage."

"This agreement represents MDS Nordion and Lantheus' commitment to provide medical isotopes to the global nuclear medicine community," said Steve West, Chief Executive Officer, MDS Inc. "The Nordion team has been actively preparing for the NRU restart and we have taken the steps necessary to assume our role in the supply chain and resume the processing of isotopes for patients worldwide."

About Molybdenum-99 and Technetium-99m

Over 21 million doses of diagnostic radiopharmaceuticals were injected into patients in the United States during 2009. Of these, 65 percent were for cardiac exams, with the remaining for oncology, neurology and other applications. Technetium-99m (Tc-99m), which is the decay product of molybdenum-99 (Mo-99), is the most commonly used medical radioisotope in the United States. At 16.7 million doses, Tc-99m accounted for 80 percent of all diagnostic radiopharmaceutical injections². Tc-99m is used in Lantheus Medical Imaging's TechnoLite® (Technetium Tc99m Generator) generators, which are distributed to radiopharmacies and hospitals as a source of Tc-99m for diagnostic imaging procedures. Tc-99m is also used with Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), one of the world's most widely-used cardiac imaging agents and the only technetium labeled myocardial perfusion agent that has been used to image more than 40 million patients. In diagnostic use, the Tc-99m is attached to a specific molecule and injected into the patient. The diagnostic medicine then travels to the site or organ of interest and a special camera is used to pick up the gamma rays emitted from the radioactive material in the body and to create images for diagnostic evaluation.

About Lantheus Medical Imaging, Inc.

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medicine for more than 50 years, is dedicated to creating and providing pioneering medical imaging solutions to improve the treatment of human disease. The company's proven success in discovering, developing and marketing innovative medical imaging agents provides a strong platform from which to bring forward breakthrough new tools for the diagnosis and management of disease. Lantheus imaging products include the echocardiography contrast agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension, ABLAVAR® (gadofosveset trisodium), a first-in-class magnetic resonance agent indicated for the evaluation of aortoiliac occlusive disease in adults with known or suspected peripheral vascular disease, TechnoLite® (Technetium Tc99m Generator), Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), and Thallium 201 (Thallous Chloride Tl 201 Injection). Lantheus has more than 600 employees worldwide with headquarters in North Billerica, Massachusetts, and offices in Puerto Rico, Canada

and Australia. For more information, visit www.lantheus.com.

1. Atomic Energy of Canada Limited. NRU Status Report #52 – AECL Provides Update on NRU Activities, Chalk River Information Bulletin. http://www.aecl.ca/NewsRoom/Community_Bulletins/100421.htm. Accessed on June 2, 2010.
2. Arlington Medical Resources, Inc., The Imaging Market Guide, 2009.